SWOG clinical trial number
SWOG-9412

Phase III Randomized Comparison of Maintenance Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil vs. High Dose Chemotherapy with Cyclophosphamide, Thiotepa and Carboplatin and Autologous Bone Marrow Support for Women with Metastatic Breast Cancer who are Responding to Conventional Induction Chemotherapy.

Closed
Phase
Published
Abbreviated Title
Conventional vs. HD Chemo+Stem Cell Transplant
Activated
07/01/1994
Closed
12/23/1997

Research committees

Breast Cancer

Treatment

Carboplatin Thiotepa CMF

Publication Information Expand/Collapse

2020

Economic evaluations in NCI-sponsored network cancer clinical trials

VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9

PMid: PMID33248521 | PMC number: PMC8262264

2000

Conventiional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer

EA Stadtmauer;A O'Neill;LJ Goldstein;PA Crilley;KF Mangan;JN Ingle;I Brodsky;S Martino;HM Lazarus;JK Erban;C Sickles;JH Glick New England Journal of Medicine 342(15):1069-1076

1999

Phase III randomized trial of high-dose chemo (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemo with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women w/met brst ca who are responding to conventional induction chemo: The Phila....

EA Stadtmauer;A O'Neill;LJ Goldstein;P Crifley;KF Mangan;JN Ingle;HM Lazarus;J Erban;C Sickles;JH Glick Proc of the American Society of Clinical Oncology 18:1a(#1)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
13%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase